SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp selloff across AI and neocloud infrastructure stocks, with traders debating financing risks, data-center spending and whether AI demand will generate returns. Some see an oversold dip and potential rebound or short squeeze, while others warn the bounce may fail and expect further losses.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy has fueled a rebound discussion after a sharp selloff, with some traders seeing the decline as overdone and others warning that CoreWeaves heavy debt and financing needs remain a risk. The debate centers on whether AI demand and contracted business can outweigh concerns about borrowing costs and the companys ability to fund its expansion.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs quarterly results beat expectations and its 2027 adjusted EBITDA outlook was raised, driving a sharp rally. Traders are debating whether strong operating momentum could fuel short covering or whether the companys debt and reliance on steel-price forecasts limit the upside.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders await the 80th death event that triggers final analysis of its Phase 3 REGAL trial; the last company-disclosed count was 78, and the threshold has not been confirmed. Some traders view the prolonged wait and upcoming ASH meeting as possible signs of encouraging survival data, while others caution that a blinded trials delay does not establish efficacy and debate whether results could be under an ASH embargo.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

X-energys proposed AEP study of a large Xe-100 plant in Indiana, with Amazon linked to long-term power demand, is drawing attention as shares slide sharply. Traders are split between buying the dip on Amazons backing and nuclear-power demand, and worrying about continued selling pressure and the long path from feasibility work to commercial reactors.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Recent competitor trial news is driving attention, particularly EyePoints failed wet-AMD study and what it may mean for Oculars AXPAXLI program. Traders are split: some worry the setback could deepen skepticism about TKI therapies, while others see reduced competition and argue AXPAXLIs data and durability are distinct.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDAs clearance to expand Alpha Taus U.S. REGAIN recurrent-glioblastoma trial from 10 to 20 patients is drawing attention, alongside expectations for additional clinical data at the SNO meeting. Traders are broadly optimistic about the growing catalyst pipeline, while the early GBM results come from a very small cohort; completion of enrollment in the pancreatic IMPACT study is also contributing to the discussion.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech selloff, attributed by traders to rising-rate concerns, risk-off positioning and rotation away from smaller biotech stocks, is weighing on XBI. The community is split between expecting further weakness and viewing the sharp pullback as an oversold buying opportunity, with potential M&A and upcoming clinical catalysts cited as reasons for optimism.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

JPMorgans upgrade of Intel to Neutral from Underweight, citing improving execution, is a key focus after a sharp selloff. Some traders see it as validation of the turnaround, while others dismiss the upgrade because the price target was unchanged; broader chip-sector weakness and unconfirmed foundry-deal speculation add to the debate.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results are drawing attention after wider mortgage spreads drove a sharp decline in book value and a reported loss, while earnings fell short of covering the monthly dividend. Traders are debating dividend sustainability and added risk from higher leverage, though some view the losses as largely unrealized and continue to favor the income stream.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's How Much You Would Have Made Owning RadNet Stock In The Last 15 Years

RadNet (NASDAQ:RDNT) has outperformed the market over the past 15 years by 12.77% on an annualized basis producing an average annual return of 25.97%. Currently, RadNet has a market capitalization of $5.63 billion.read more...

The Pennant Group (PNTG) Moves 6.3% Higher: Will This Strength Last?

The Pennant Group (PNTG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised

RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.

RadNet (RDNT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for RadNet (RDNT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

Outset Medical (OM) delivered earnings and revenue surprises of -26.98% and +9.84%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Countdown to RadNet (RDNT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Besides Wall Street's top-and-bottom-line estimates for RadNet (RDNT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

Encompass Health (EHC) Beats Q2 Earnings and Revenue Estimates

Encompass Health (EHC) delivered earnings and revenue surprises of +4.73% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

RDNT's Unit DeepHealth Expands AI Breast Suite With FDA-Cleared Tools

RadNet's DeepHealth gains FDA clearances for AI breast imaging tools that assess cardiovascular risk and compare prior mammograms.

Do Options Traders Know Something About RadNet Stock We Don't?

Investors need to pay close attention to RDNT stock based on the movements in the options market lately.

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts PR Newswire NEW YORK, May 19...

RadNet, Inc. engages in the provision of outpatient diagnostic imaging services in the United States. It operates through the following segments: Imaging Centers and Digital Health. The Imaging Centers segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. The Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.

Radnet Inc

iCAD Stock Rockets On Merger Announcement With RadNet: Retail’s Elated

Equity

Neutral Sentiment

Shares of AI-powered breast health solutions provider iCAD, Inc. (ICAD) rocketed over 67% on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.icadmed.com/about/news-events/press-releases/radnet-inc-to-acquire-icad-inc-to-accelerate-ai-powered-early-detection-and-diagnosis-of-breast-cancer/">said</a> it entered a definitive merger agreement with RadNet (RDNT).Diagnostic imaging services provider RadNet will acquire iCAD in an all-stock transaction where iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger.Based upon RadNet’s closing price on Monday, this represents a transaction value of approximately $103 million, or approximately $3.61 per share of iCAD common stock on a fully diluted basis and an approximately 98% premium to iCAD stockholders based on iCAD’s closing stock price on Monday, the company said.The transaction is expected to close in the second or third quarter of 2025, subject to approval by iCAD stockholders. It is expected to add to RadNet’s wholly-owned unit DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries.RadNet CEO Howard Berger said that iCAD’s ProFound Breast Health Suite and RadNet’s DeepHealth AI-powered breast screening solutions together have the power to improve patient diagnosis of breast cancer.“With over 1,500 healthcare provider locations, facilitating over eight million annual mammograms in 50 countries, iCAD’s installed base and strong sales, engineering, and marketing capabilities will provide us with immediate broad and valuable customer relationships and commercialization capabilities that can accelerate our existing DeepHealth objectives,” he said.RadNet stock fell by about 7% on Wednesday.On Stocktwits, retail sentiment around iCAD rose from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘extremely low’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:652/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_10_23_43_AM_png_7dae918bc5.webp" alt="ICAD's Sentiment Meter and Message Volume as of 10:20 a.m. ET on April 16, 2025 | Source: Stocktwits" width="652" height="146"><figcaption>ICAD's Sentiment Meter and Message Volume as of 10:20 a.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ICAD">ICAD stock</a> is up by over 62% year-to-date and has more than doubled over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/travelers-q1-2025-earnings/chQPN6URbOo">Travelers Q1 2025 Earnings Beat Wall Street Estimates Despite $2.26 Billion California Wildfires Losses, Revenue Falls Short Of Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Diagnostic imaging services provider RadNet will acquire iCAD in an all stock transaction where iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger.

Icad Inc

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$68.80
Prev Close	$70.41
Open	$70.41
Dividend Yield	0.00%
50-Day Moving Average	$73.50
Beta	1.21
Avg. Volume	786,677.79
PE Ratio	-248.82

52-Week High	$85.84
52-Week Low	$50.82
Market Capitalization	$5.41B
EPS (Annual)	-$0.2481
Price to Book	4.94
Revenue Per Employee	$230,688.60

Feed

News

Sentiment

Earnings

Fundamentals

Info

RDNT Fundamentals